Out of the lab, into the courts
Article Abstract:
The Adelaide biotechnology company BresaGen is planning to terminate the phase-two trial of a potential anti-cancer drug called E21R. The project of E21R was important to the company because of a lucrative collaboration deal it had signed in 2000 with the listed British Biotech to develop the cancer drug.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Now hear this
Article Abstract:
The business growth plans of Neuromonics, in the United States, are presented.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Ansell thinks bigger
Article Abstract:
The expansion plans of Ansell in China are examined.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Nuts for the winter. Mini miners rule. How to work in the US
- Abstracts: The world awaits. No minor parts. Debt of gratitude
- Abstracts: Why togetherness works. Low fat, high profit. Mister international
- Abstracts: When you sign an AWA you are contracting yourself to the company. Everyone is becoming their own business. Suit yourself
- Abstracts: Make the baseline forecast your trusted advisor. Sales and operations planning part III: a diagnostic model